842 related articles for article (PubMed ID: 8682064)
1. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
Sigurdsson A; Swedberg K
Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
[TBL] [Abstract][Full Text] [Related]
2. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
Sigurdsson A
Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure.
Konstam MA
Eur Heart J; 1995 Dec; 16 Suppl N():59-64. PubMed ID: 8682063
[TBL] [Abstract][Full Text] [Related]
4. Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.
Sigurdsson A; Eriksson SV; Hall C; Kahan T; Swedberg K
Eur J Heart Fail; 2001 Jan; 3(1):69-78. PubMed ID: 11163738
[TBL] [Abstract][Full Text] [Related]
5. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
[TBL] [Abstract][Full Text] [Related]
7. Congestive heart failure: what should be the initial therapy and why?
Chatterjee K
Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
[TBL] [Abstract][Full Text] [Related]
8. Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition.
Foy SG; Crozier IG; Richards AM; Nicholls MG; Turner JG; Frampton CM; Ikram H
Eur Heart J; 1995 Jun; 16(6):770-8. PubMed ID: 7588920
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
10. Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure.
Kinugawa T; Kato M; Mori M; Endo A; Kato T; Hamada T; Noguchi N; Omodani H; Osaki S; Ogino K; Miyakoda H; Hisatome I; Shigemasa C
Eur J Clin Pharmacol; 1998 May; 54(3):209-14. PubMed ID: 9681661
[TBL] [Abstract][Full Text] [Related]
11. Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure.
van Veldhuisen DJ; Boomsma F; de Kam PJ; Man in't Veld AJ; Crijns HJ; Hampton JR; Lie KI
Eur Heart J; 1998 May; 19(5):753-60. PubMed ID: 9717009
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
Roig E; Perez-Villa F; Morales M; Jiménez W; Orús J; Heras M; Sanz G
Eur Heart J; 2000 Jan; 21(1):53-7. PubMed ID: 10610744
[TBL] [Abstract][Full Text] [Related]
13. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Tsuyuki RT; Yusuf S; Rouleau JL; Maggioni AP; McKelvie RS; Wiecek EM; Wang Y; Pogue J; Teo KK; White M; Avezum A; Latini R; Held P; Lindgren E; Probstfield J
Can J Cardiol; 1997 Dec; 13(12):1166-74. PubMed ID: 9444298
[TBL] [Abstract][Full Text] [Related]
14. Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Düsseldorf, Munich, Germany.
Nussberger J; Fleck E; Bahrmann H; Delius W; Schultheiss HP; Brunner HR
Eur Heart J; 1994 Dec; 15 Suppl D():113-22. PubMed ID: 7713100
[TBL] [Abstract][Full Text] [Related]
15. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
MacFadyen RJ; Lees KR; Reid JL
Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
[TBL] [Abstract][Full Text] [Related]
16. [Value of ACE inhibitors in heart failure (clinical aspects)].
Riegger AJ
Z Kardiol; 1992; 81 Suppl 4():93-6. PubMed ID: 1290309
[TBL] [Abstract][Full Text] [Related]
17. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
[TBL] [Abstract][Full Text] [Related]
18. Lessons from recent randomized controlled trials for the management of congestive heart failure.
Riegger GA
Am J Cardiol; 1993 Jun; 71(17):38E-40E. PubMed ID: 8328366
[TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
Beckwith C; Munger MA
Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
[TBL] [Abstract][Full Text] [Related]
20. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
Lee AF; MacFadyen RJ; Struthers AD
Eur J Heart Fail; 1999 Dec; 1(4):401-6. PubMed ID: 10937954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
